Please use this identifier to cite or link to this item:
Title: Immunogenicity and immunization costs of adjuvanted versus non-adjuvanted hepatitis B vaccine in chronic kidney disease patients
Author: Vilajeliu, Alba
Sequera, Víctor_Guillermo
García-Basteiro, Alberto L.
Sicuri, Elisa
Aldea, Marta
Velasco, César
Bayas Rodríguez, José María
Keywords: Hepatitis B
Malalties del ronyó
Hepatitis B
Kidney diseases
Issue Date: 22-Apr-2016
Publisher: Taylor & Francis
Abstract: Hepatitis B virus (HBV) vaccination is recommended for all susceptible chronic pre-hemodialysis and hemodialysis patients. This study assessed the immunogenicity of HBV vaccines (adjuvanted and non-adjuvanted) in chronic kidney disease patients vaccinated at the Hospital Clinic of Barcelona (Spain) between January 2007 and July 2012. In addition, the costs for the health system were evaluated according to the proportion of vaccine responders after receiving either vaccine. Patients receiving three doses of hepatitis B adjuvanted vaccine were three times more likely to seroconvert than patients immunized with non-adjuvanted vaccines, OR 3.56 (95% CI 1.84-6.85). This resulted in fewer patients requiring a second course of HBV vaccination and fewer outpatient visits, saving more than euro9,500 per 100 patients. The higher immunogenicity of the adjuvanted HBV vaccine would counterbalance the lower costs associated with the non-adjuvanted vaccine.
Note: Versió postprint del document publicat a:
It is part of: Human Vaccines & Immunotherapeutics, 2016
Related resource:
ISSN: 2164-5515
Appears in Collections:Articles publicats en revistes (ISGlobal)

Files in This Item:
File Description SizeFormat 
vilajeliu2016_2119.pdf367.39 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.